Harbin Gloria Pharmaceuticals (002437) — Cash Flow Reinvestment Rate
Harbin Gloria Pharmaceuticals (002437) has a Cash Flow Reinvestment Rate of 0.02x as of September 2025, reinvesting CN¥4.26 Million (capex CN¥4.26 Million ) from operating cash flow of CN¥182.89 Million. See Harbin Gloria Pharmaceuticals free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Harbin Gloria Pharmaceuticals Cash Flow Reinvestment Rate (2007–2025)
Historical reinvestment intensity for Harbin Gloria Pharmaceuticals across 19 annual periods. For the full cash flow conversion analysis, see 002437 cash generation efficiency.
Annual Cash Flow Reinvestment Rate for Harbin Gloria Pharmaceuticals (2007–2025)
Year-by-year capital reinvestment analysis for Harbin Gloria Pharmaceuticals. See financial agility of Harbin Gloria Pharmaceuticals to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.26x | CN¥343.47 Million | CN¥273.36 Million | CN¥23.81 Million | ▲ +589.1% |
| 2024 | 0.18x | CN¥74.93 Million | CN¥410.94 Million | CN¥62.90 Million | ▼ -59.7% |
| 2023 | 0.45x | CN¥124.00 Million | CN¥274.18 Million | CN¥29.62 Million | ▼ -53.9% |
| 2022 | 0.98x | CN¥256.90 Million | CN¥261.62 Million | CN¥33.01 Million | ▲ +306.9% |
| 2021 | 0.24x | CN¥66.17 Million | CN¥274.18 Million | CN¥34.51 Million | ▼ -94.4% |
| 2020 | 4.29x | CN¥54.70 Million | CN¥12.76 Million | CN¥43.66 Million | ▲ +1995.1% |
| 2019 | 0.20x | CN¥124.85 Million | CN¥610.37 Million | CN¥48.43 Million | ▼ -33.3% |
| 2018 | 0.31x | CN¥356.67 Million | CN¥1.16 Billion | CN¥104.34 Million | ▼ -30.0% |
| 2017 | 0.44x | CN¥285.52 Million | CN¥651.80 Million | CN¥194.63 Million | ▲ +14.4% |
| 2016 | 0.38x | CN¥398.39 Million | CN¥1.04 Billion | CN¥185.34 Million | ▼ -39.2% |
| 2015 | 0.63x | CN¥442.37 Million | CN¥702.05 Million | CN¥283.10 Million | ▲ +237.4% |
| 2014 | 0.19x | CN¥125.89 Million | CN¥674.04 Million | CN¥125.89 Million | ▼ -48.2% |
| 2013 | 0.36x | CN¥163.35 Million | CN¥453.02 Million | CN¥163.35 Million | ▼ -48.6% |
| 2012 | 0.70x | CN¥144.37 Million | CN¥205.89 Million | CN¥144.37 Million | ▼ -46.0% |
| 2011 | 1.30x | CN¥166.90 Million | CN¥128.61 Million | CN¥166.90 Million | ▼ -39.3% |
| 2010 | 2.14x | CN¥240.88 Million | CN¥112.59 Million | CN¥240.88 Million | ▲ +494.5% |
| 2009 | 0.36x | CN¥61.47 Million | CN¥170.82 Million | CN¥61.47 Million | ▼ -45.4% |
| 2008 | 0.66x | CN¥38.08 Million | CN¥57.81 Million | CN¥38.08 Million | ▲ +161.3% |
| 2007 | 0.25x | CN¥13.17 Million | CN¥52.26 Million | CN¥13.17 Million | — |